DMAA resets Power Analytics merger at $2.85B fixed valuation
What's the deal? Drugs Made In America Acquisition CorpDealroom has a profile for this one. Try Dealroom → (Nasdaq: DMAA) signed an amended merger agreement with Power Analytics Global CorpDealroom has a profile for this one. Try Dealroom → (PAGC) on September 8, 2026, resetting terms and fixing PAGC's equity value at $2.85 billion. The figure includes APQC IncDealroom has a profile for this one. Try Dealroom → and the UltraSolar intellectual property.
Why now? The revised deal replaces an earlier framework that pegged PAGC at $1 billion, tied to a milestone schedule and a $300 million floor. DMAA's board had authorised a valuation of up to $3 billion on August 5, 2026, then approved the $2.85 billion figure a month later.
What are the mechanics? Merger consideration equals the closing valuation divided by a reference price — the greater of $10.75 or DMAA's per-share redemption value. Because the price cannot fall below $10.75, share issuance is capped at 265,116,279 shares. No fractional shares or cash-in-lieu will be issued.
The deal is structured as a domestication of DMAA from the Cayman Islands to Delaware, followed by a merger that leaves PAGC as a wholly owned DMAA subsidiary.
What are the conditions? Before closing, PAGC must acquire 100% of APQC Inc and the UltraSolar patents under a letter of intent dated July 23, 2026. DMAA may terminate if that acquisition is not completed by December 31, 2026. The merger also requires at least $15 million in available closing cash, without credit-facility proceeds, against a $30 million target.
What could go wrong? PAGC and BV Advisory PartnersDealroom has a profile for this one. Try Dealroom →, which holds DMAA convertible notes entitled to at least 40% of sponsor-level economics, are under common principal ownership, making this an affiliated combination. To address the conflict, DMAA engaged Newbridge Securities CorporationDealroom has a profile for this one. Try Dealroom → on September 8, 2026 for a fairness opinion, with a fee not contingent on its conclusion or on completion.
Key decisions on valuation, structure, and termination are reserved to DMAA's independent and disinterested directors. The outside termination date is April 29, 2027, extendable by mutual agreement.
The signal: Swapping a milestone-based structure for a single fixed number simplifies the arithmetic but shifts more weight onto conditions still to be met — chiefly the APQC acquisition and the cash minimum. With affiliated ownership on both sides, the independent directors and outside fairness review become the deal's main guardrails.
Read more: minichart.com.sg
Image credit: Generated with Gemini
